Skip to main content
OpenTrials
Completed

NCT Number: NCT06066541

Social Norms, Messengers, and Processing Fluency to Increase Hypertension Medication Adherence

Medicare Advantage beneficiaries ages 65-79 and insured by Humana with at least two unique fills of hypertension medication within the 2023 calendar year and adherence level between 60 and 85% will be identified using Humana Medicare Advantage claims data. Individuals meeting these inclusion criteria will be included and, with an institutional review board approved waiver of informed consent, will be randomized to one of 6 mailed messages or control (no message). The messages will be sent by Humana and use different behavioral techniques (social norms, messenger effects, and/or processing fluency) providing their medication refill score. Humana will send a second message within 60 days of the first message noting any changes in the refill score.

The primary outcome will be the average end-of-year adherence in each arm. A secondary outcome will be the proportion of study participants with end-of-year adherence greater than or equal to 80%. The study team's hypothesis is that messages using dynamic social norms, messenger effects, and processing fluency in combination will more effectively increase average end-of-year adherence level compared to usual care.

Humana will conduct all study participant outreach and data analyses, which will be performed using routinely collected insurance claims data. Regulatory oversight is conducted using Humana's centralized institutional review board (IRB) of record. The work completed by Humana study staff is funded by Humana, Inc.

Dr. Choudhry and his colleagues (including subaward recipients ideas42 and Tuck School of Business at Dartmouth) will provide technical and subject matter expertise related to study research design and implementation, protocol design, statistical analysis, publication (abstract, poster, manuscript) preparation and/or review, and assistance throughout the peer review process including revisions and additional analyses if necessary for this project. The work completed by study staff at Brigham and Women's Hospital, ideas42, and Tuck School of Business at Dartmouth is funded by NIA.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Humana, Inc.

Louisville, Kentucky, 40202, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Medicare Advantage beneficiary insured by Humana
  • Between the ages of 65 and 79
  • Having at least two unique fills of any class of hypertension medication within the calendar year (2023).
  • Adherence level (as measured by the proportion of days covered [PDC] metric) between 60% and 85%

Exclusion criteria

  • Beneficiaries in plans which, per contractual agreements, privacy policies and rules, or legal requirements, do not participate in research

Treatment and study plan

Scorecard

Behavioral

Participants will be mailed a scorecard from Humana reporting patients' medication adherence using a "refill score."

Social norms

Behavioral

Participants will be mailed a dynamic social norms messaging (noting the proportion of Humana members improving their medication refill scores).

Messenger effects

Behavioral

Participants will be mailed a scorecard coming from the trusted messenger of a Humana-identified pharmacist taking the same medication.

Processing fluency

Behavioral

Participants will be mailed a modified scorecard increasing processing fluency through a visual metaphor of "closing the ring."

Primary outcomes

  1. Average End-of-year Adherence Level

    Time frame: approximately 4 months

    The primary outcome will be the average end-of-year adherence level in each arm (as measured by the Proportion of Days Covered metric [PDC]) stratified by refill cycle and adjusting for age, sex, and race.

Secondary outcomes

  1. Proportion of Participants With End-of-year PDC≥80%

    Time frame: approximately 4 months

    As measured by the Proportion of Days Covered metric [PDC]

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

  • Humana Inc.
  • National Institute on Aging (NIA)

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Oct 4, 2023
Registry last updated
Jan 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.